Alto Neuroscience Files Q1 2025 10-Q
Ticker: ANRO · Form: 10-Q · Filed: May 14, 2025 · CIK: 1999480
| Field | Detail |
|---|---|
| Company | Alto Neuroscience, Inc. (ANRO) |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, quarterly-report, pharmaceuticals
TL;DR
Alto Neuroscience Q1 2025 10-Q filed. Financials updated.
AI Summary
Alto Neuroscience, Inc. filed its quarterly report for the period ending March 31, 2025. The company, focused on pharmaceutical preparations, reported its financial status as of this date. Key financial data and operational details for the first quarter of 2025 are presented in this filing.
Why It Matters
This filing provides investors with an update on Alto Neuroscience's financial health and operational progress during the first quarter of 2025, crucial for assessing the company's trajectory.
Risk Assessment
Risk Level: medium — As a clinical-stage pharmaceutical company, Alto Neuroscience faces inherent risks related to drug development and regulatory approvals.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial information is reported.)
- 2025-05-14 — Filing Date (The date the 10-Q report was officially submitted to the SEC.)
- 2024-03-31 — Prior Year Quarter End Date (Provides a comparative point for financial performance analysis.)
Key Players & Entities
- Alto Neuroscience, Inc. (company) — Filer of the 10-Q report
- 20250331 (date) — End of the reporting period
- 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
- 650 CASTRO STREET, SUITE 450 (address) — Company's business and mailing address
- MOUNTAIN VIEW, CA (location) — City and State of the company's address
FAQ
What is the primary business of Alto Neuroscience, Inc.?
Alto Neuroscience, Inc. is primarily involved in Pharmaceutical Preparations, as indicated by its SIC code 2834.
What period does this 10-Q filing cover?
This 10-Q filing covers the period ending March 31, 2025.
When was this 10-Q report filed with the SEC?
This 10-Q report was filed on May 14, 2025.
What is the company's principal business address?
The company's principal business address is 650 Castro Street, Suite 450, Mountain View, CA 94041.
What is the fiscal year end for Alto Neuroscience?
Alto Neuroscience's fiscal year ends on December 31.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding Alto Neuroscience, Inc. (ANRO).